FoxHollow seek US nod for NightHawk:
This article was originally published in Clinica
Executive Summary
FoxHollow Technologies has submitted to the US FDA a 510(k) marketing application for its NightHawk system for visualising and excising plaque from peripheral arteries. The product brings together optical coherence tomography (OCT) with the firm's FDA-cleared SilverHawk plaque excision system. It uses fibre-optic technology embedded in the catheter and allows the physician to visualise in real-time the vascular morphology and wall structures. The OCT-embedded catheters are designed for use as an adjunct to conventional angiography to provide an image of the vessel lumen and wall structures. Separately, the Redwood City, California firm has launched a faster and easier-to-use version of SilverHawk, called SilverHawk SXL.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.